Therapeutic potential of low-dose IL-2 in a chronic GVHD patient by in vivo expansion of regulatory T cells |
| |
| Institution: | 1. The Institute for Translational Research and Molecular Imaging, The Catholic University of Korea College of Medicine, Seoul, Republic of Korea;2. Laboratory of Immune Regulation, Convergent Research Consortium for Immunologic Disease, Seoul, Republic of Korea;3. The Catholic Blood and Marrow Transplantation Center, Seoul St. Mary’s Hospital, The Catholic University of Korea College of Medicine, Seoul, Republic of Korea;1. Severance Cardiovascular Hospital, Yonsei University Health System, Seoul, Korea;2. Cardiovascular Research Institute, Yonsei University College of Medicine, Seoul, Korea;3. Department of Optical Engineering, Sejong University, Seoul, Korea;4. Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Korea;1. Fred Hutchinson Cancer Research Center and Department of Pediatrics, University of Washington, Seattle, WA;2. Cincinnati Children''s Hospital, Cincinnati, OH;3. Seattle Children''s Research Institute and Department of Pediatrics, University of Washington, Seattle, WA;4. Boston Children''s Hospital and Department of Pediatrics, Harvard Medical School, Boston, MA;5. Division of Blood and Marrow Transplantation, Department of Pediatrics, University of Minnesota, Minneapolis, MN;6. Department of Genome Sciences, University of Washington, Seattle, WA;1. Transplant Research Center, Seoul St. Mary''s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea;2. Division of Nephrology, Department of Internal Medicine, Seoul St. Mary''s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea;1. Academy of Electronic, Electrical and Computer Engineering, Xiamen Institute of Technology, No.1251, Sunban South Road, Jimei District, Xiamen, 361021, China;2. College of Information Science and Engineering, Huaqiao University, No. 668, Jimei Avenue, Jimei District, Xiamen, 361021, Fujian, China;1. Center for Immunity and Immunotherapies, Seattle Children’s Research Institute, Seattle, WA, USA;2. Department of Pediatrics, University of Washington, Seattle, WA, USA |
| |
| Abstract: | Chronic graft-versus-host disease (cGVHD) is a common complication following allogeneic hematopoietic stem cell transplantation (HSCT), which is characterized by autoimmune like inflammatory responses and reduced levels of regulatory T cells (Tregs). Recently, the use of low-dose IL-2 has been reported to selectively increase Tregs and therefore facilitate immune regulation and promote clinical improvements in cGVHD patients. In this report, we describe the case of a cGVHD patient who was treated with daily low-dose IL-2 therapy. Our observations demonstrate that low-dose IL-2 could induce significant expansion of Tregs in vivo leading to improved Treg/Th17 ratios. The patient showed moderate clinical benefits suggesting that multiple factors may be involved in the immunological responses. Therefore, while the therapeutic potential of low-dose IL-2 is promising, strategic approaches may be needed to induce a clinically significant and sustained Treg effect. |
| |
| Keywords: | Chronic graft-versus-host disease Interleukin-2 Regulatory T cell Immunotherapy Allogeneic hematopoietic stem cell transplantation |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
